|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
1999
|
|
gptkbp:ATCCode
|
N03AX14
|
|
gptkbp:brand
|
gptkb:Keppra
gptkb:Elepsia_XR
gptkb:Spritam
|
|
gptkbp:CASNumber
|
102767-28-2
|
|
gptkbp:chemicalFormula
|
C8H14N2O2
|
|
gptkbp:contraindication
|
hypersensitivity to levetiracetam
|
|
gptkbp:discoveredBy
|
gptkb:UCB_Pharma
|
|
gptkbp:drugClass
|
anticonvulsant
|
|
gptkbp:eliminationHalfLife
|
6-8 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:form
|
gptkb:tablet
intravenous solution
oral solution
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:genericName
|
gptkb:levetiracetam
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Keppra
|
|
gptkbp:indication
|
myoclonic seizures
tonic-clonic seizures
partial onset seizures
|
|
gptkbp:interactsWith
|
other antiepileptic drugs
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:UCB_Pharma
|
|
gptkbp:marketedIn
|
gptkb:Europe
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
modulates synaptic neurotransmitter release
|
|
gptkbp:notableFor
|
low potential for drug interactions
|
|
gptkbp:patentExpired
|
2009 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adults
children
|
|
gptkbp:prescriptionRequired
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
dizziness
fatigue
headache
loss of appetite
drowsiness
irritability
|
|
gptkbp:usedFor
|
epilepsy
seizure disorders
|
|
gptkbp:bfsParent
|
gptkb:UCB_Biopharma
gptkb:UCB_Pharma
gptkb:levetiracetam
gptkb:Levetiracetam
|
|
gptkbp:bfsLayer
|
7
|